Remy Luthringer
Overview
Explore the profile of Remy Luthringer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lotharukpong J, Zheng M, Luthringer R, Liesner D, Drost H, Coelho S
Nature
. 2024 Oct;
635(8037):129-135.
PMID: 39443791
Complex multicellularity has emerged independently across a few eukaryotic lineages and is often associated with the rise of elaborate, tightly coordinated developmental processes. How multicellularity and development are interconnected in...
2.
James S, Ahmed A, Harvey P, Saoud J, Davidson M, Kuchibhatla R, et al.
Eur Neuropsychopharmacol
. 2024 Jul;
87:18-23.
PMID: 39024856
Roluperidone, a 5-HT, sigma, and ɑ-adrenergic receptor antagonist, has proven efficacious for treating negative symptoms of schizophrenia in phase 2b and phase 3 clinical trials. Using network analysis, we demonstrated...
3.
Luthringer R, Raphalen M, Guerra C, Colin S, Martinho C, Zheng M, et al.
Science
. 2024 Mar;
383(6689):eadk5466.
PMID: 38513029
In many eukaryotes, genetic sex determination is not governed by XX/XY or ZW/ZZ systems but by a specialized region on the poorly studied U (female) or V (male) sex chromosomes....
4.
Rabinowitz J, Staner C, Saoud J, Weiser M, Kuchibhatla R, Davidson M, et al.
Schizophr Res
. 2023 Mar;
255:9-13.
PMID: 36933291
Roluperidone has antagonist properties for 5-HT, sigma, α- and α-adrenergic receptors, but no dopaminergic binding affinities. In 2 randomized controlled trials (RCT), treatment improved negative symptoms of schizophrenia and social...
5.
Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, et al.
Schizophr Bull
. 2022 Feb;
48(3):609-619.
PMID: 35211743
Background: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT2A, sigma2, and α1A-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows...
6.
Heesch S, Serrano-Serrano M, Barrera-Redondo J, Luthringer R, Peters A, Destombe C, et al.
J Evol Biol
. 2021 Jun;
34(7):992-1009.
PMID: 34096650
A vast diversity of types of life cycles exists in nature, and several theories have been advanced to explain how this diversity has evolved and how each type of life...
7.
Daniel D, Kott A, Saoud J, Luthringer R, Rud V, Skyrpnikov A, et al.
Innov Clin Neurosci
. 2020 Jun;
17(1-3):27-29.
PMID: 32547844
Patients with schizophrenia who, prior to inclusion in placebo-controlled trials, experience the most severe and/or unstable symptoms might be more likely to manifest symptomatic worsening upon antipsychotic discontinuation. This retrospective...
8.
Strauss G, Zamani Esfahlani F, Sayama H, Kirkpatrick B, Opler M, Saoud J, et al.
Schizophr Bull
. 2020 Jan;
46(4):964-970.
PMID: 31989151
A recent conceptual development in schizophrenia is to view its manifestations as interactive networks rather than individual symptoms. Negative symptoms, which are associated with poor functional outcome and reduced rates...
9.
Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, Van Der Ark P, et al.
Transl Psychiatry
. 2019 Oct;
9(1):240.
PMID: 31578318
In the original Article, Tables two and three had formatting issues which affected their clarity. This has been corrected in the PDF and HTML versions of this Article.
10.
Harvey P, Saoud J, Luthringer R, Moroz S, Blazhevych Y, Stefanescu C, et al.
Schizophr Res
. 2019 Sep;
215:352-356.
PMID: 31488314
Background: Recent research has suggested that negative symptoms (NS) can be considered in terms of two different dimensions: reduced expression (expressive deficit) and reduced experience (experiential deficit). Roluperidone, a compound...